AstraZeneca (AZN.L) News and Global Pharmaceutical & Healthcare Updates
164.5
4.9700
2.93 %
At close
07/14
USD
Daily range
164.50
167.82
167.82
Weekly range
168.11
191.48
191.48
HSBC cuts AstraZeneca to hold as trial setback clouds valuation outlook
AstraZeneca faces fresh pressure after a late-stage heart disease trial misses its target and triggers a sharp share selloff. The setback prompts HSBC to abandon its bullish stance on the ...
Will AstraZeneca stock avoid deeper losses as sellers dominate the short-term trend?
AstraZeneca (AZN) stock is trading at GBX12,444, reflecting a decline of 1.32% compared to the prior close. The price sits below its key moving averages, showing ...
AstraZeneca stock outlook: Support pressure builds amid seller control
AstraZeneca (AZN) stock is trading at GBX12,658, down 1.37% for the day. The price remains below its key moving averages, signaling continued weakness relative to recent ...
AZN slides over 3% as Wainua Phase III clinical trial fails to meet efficacy goals
AstraZeneca PLC (AZN) dropped 3.03% after its late-stage Phase III CARDIO-TTRansform clinical trial for heart drug Wainua failed to meet its primary efficacy endpoint, triggering pronounced ...
AstraZeneca shares remain under pressure after trial failure
AstraZeneca shares remain under pressure following disappointing results from a key late-stage clinical trial. In the near term, the company's upcoming quarterly earnings report is likely to be ...
Why is AstraZeneca stock down today?
AstraZeneca (AZN) stock is trading at GBX13,178 after declining 1.32% for the day. The price is currently positioned below its key moving averages, indicating ongoing ...
What's behind AstraZeneca's latest 9.1% stock pullback?
AstraZeneca PLC (AZN) fell 9.06% after its late-stage Wainua trial for the treatment of ATTR-CM failed to meet its primary endpoint, triggering sharp selling pressure. The downward move is ...
Why is AstraZeneca stock down today?
AstraZeneca PLC (AZN) slumped 9.37% after its late-stage heart disease trial did not achieve its main endpoints, marking a sharp single-day decline. Persistent bearish signals from the technical ...
AstraZeneca shares plunge over 9% as heart disease drug trial misses key goal
AstraZeneca PLC (AZN) sank 9.02% today after its late-stage heart disease clinical trial failed to meet its primary endpoints, driving a sharp wave of selling. The move is reinforced by persistent ...
AstraZeneca shares plunge around 9.5% as late-stage heart drug trial fails
AstraZeneca PLC (AZN) fell 9.59% after the failure of a late-stage clinical trial for a heart disease treatment drove a sharp loss of confidence in the company's development pipeline. The drop is ...
Why is AstraZeneca stock down today?
AstraZeneca PLC (AZN) plunged 10.07% after its Wainua drug failed a key Phase III trial for heart disease, erasing £19 billion in market value. The steep decline is supported by persistent ...
What's behind AstraZeneca's latest 8.4% stock pullback?
AstraZeneca PLC (AZN) dropped 8.43% after the phase III CARDIO-TTRansform trial for Wainua (eplontersen) failed to meet its primary goal, triggering a pronounced decline. The move is strongly ...
Why is AstraZeneca stock down today?
AstraZeneca PLC (AZN) tumbled 8.74% after results showed its Wainua (eplontersen) drug failed a Phase III clinical trial in transthyretin amyloid cardiomyopathy, triggering a sharp selloff and ...
What's behind AstraZeneca's latest 9.4% stock pullback?
AstraZeneca (AZN) stock is trading at GBX12,900, down 9.41% on the day with a pronounced move lower. The shares currently sit below their key moving averages, reflecting ...
AstraZeneca shares slide after heart drug trial misses key target
A late-stage setback for AstraZeneca's cardiovascular pipeline is sending its shares sharply lower in London trading. The company says Wainua fails to meet the main goal in a study for a rare ...
AstraZeneca shares fall after Wainua trial misses heart death goal
AstraZeneca faces fresh pressure in its drug pipeline after a late-stage study of Wainua fails to achieve its main objective in heart disease. The setback hits the UK drugmaker weeks after a U.S. ...
What's behind AstraZeneca's latest 1.6% stock pullback?
AstraZeneca PLC (AZN) fell 1.62% after the company announced several major licensing and co-development agreements, including a new global license for TQC3721 and a collaboration with Helix, even ...
Why is AstraZeneca stock down today?
AstraZeneca (AZN) stock is trading at GBX14,216, marking a 1.03% decline for the session. The price currently sits below its key short- and medium-term moving averages ...
AZN climbs more than 2% after CSPC deal and fresh EU drug approval
AstraZeneca PLC (AZN) surged 2.31% following continued positive momentum tied to its latest strategic partnership and fresh regulatory approvals. The move is supported by the asset’s position ...
What's behind AstraZeneca's latest 1.6% stock surge?
AstraZeneca PLC (AZN) jumped 1.65% after news of a major co-development deal with CSPC Pharmaceutical Group fueled buying, alongside fresh European approval for its Enhertu therapy. The gain is ...
What's driving AstraZeneca higher today?
AstraZeneca (AZN) stock is trading at GBX14,166, marking a modest gain for the day. The price remains positioned below its key short- and medium-term moving averages, ...
